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BACKGROUND: Recently, a Risk of Ovarian Malignancy Algorithm (ROMA) utilising human epididymis secretory protein 4 (HE4) and
CA125 successfully classified patients as presenting a high or low risk for epithelial ovarian cancer (EOC). We validated this algorithm
in an independent prospective study.
METHODS: Women with a pelvic mass, who were scheduled to have surgery, were enrolled in a prospective study. Preoperative serum
levels of HE4 and CA125 were measured in 389 patients. The performance of each of the markers, as well as that of ROMA, was
analysed.
RESULTS: When all malignant tumours were included, ROMA (receiver operator characteristic (ROC)-area under curve
(AUC)¼0.898) and HE4 (ROC-AUC)¼0.857) did not perform significantly better than CA125 alone (ROC–AUC¼0.877).
Using a cutoff for ROMA of 12.5% for pre-menopausal patients, the test had a sensitivity of 67.5% and a specificity of 87.9%. With
a cutoff of 14.4% for post-menopausal patients, the test had a sensitivity of 90.8% and a specificity of 66.3%. For EOC vs benign
disease, the ROC–AUC of ROMA increased to 0.913 and for invasive EOC vs benign disease to 0.957.
CONCLUSION: This independent validation study demonstrated similar performance indices to those recently published. However, in
this study, HE4 and ROMA did not increase the detection of malignant disease compared with CA125 alone. Although the initial
reports were promising, measurement of HE4 serum levels does not contribute to the diagnosis of ovarian cancer.
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The majority of women who undergo surgery for an ovarian cyst
or pelvic mass are treated in a community hospital by a
gynaecologist or general surgeon. Although this is appropriate
for patients who have a benign cyst, patients with a malignancy
should be referred to a tertiary care centre with multidisciplinary
teams specialised in ovarian cancer treatment. A recent systematic
review showed an improved outcome for patients with ovarian
cancer when they were referred to, and surgically treated by,
gynaecological oncologists (du Bois et al, 2009). Therefore, it is
important to triage women with increased risk for ovarian cancer
to the appropriate surgeon and centre.
CA125 is the most widely used tumour marker in ovarian cancer
(Bast et al, 1983). The sensitivity and specificity of CA125 are far
from ideal as its levels are raised in approximately 80% of all
epithelial ovarian cancers (EOC) and in only 50% of stage I EOC
(Zurawski et al, 1988). Therefore, CA125 is rarely used as
a unique parameter in the prediction of malignancy. Usually, a
combination of a patient’s medical history, clinical examination
results, imaging data and tumour marker profile is used to
differentiate malignant ovarian masses from their benign counter-
parts. Ultrasound has an important role in differentiating between
benign and malignant adnexal masses, but experience and proper
training are of paramount importance in distinguishing both
adnexal masses (Van Holsbeke et al, 2009). This highlights a major
problem in that the centre with the least experience in dealing with
malignant disease requires substantial experience in ultrasound
to triage patients to a gynaecological oncologist. This explains
the tremendous amount of effort that has been expended over
the past few decades to find new ovarian cancer biomarkers that
could be used together with, or instead of, CA125. In 1999, the
human epididymis secretory protein 4 (HE4) gene was found to be
overexpressed in ovarian cancer (Schummer et al, 1999). It is a
member of the Wey acidic protein gene family (Bouchard et al,
2006), and is expressed in normal tissues of the reproductive and
respiratory tract (Bingle et al, 2002; Galgano et al, 2006). The first
report mentioning HE4 as a potential serum biomarker for ovarian
cancer was published in 2003 (Hellstrom et al, 2003). Recently,
Moore et al (2008b, 2009) published a series of papers that used a
combination of CA125, HE4 and menopausal status to predict the
presence of a malignant ovarian tumour. Originally, nine potential
biomarkers were evaluated, of which HE4 was the most effective
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sin detecting ovarian cancer. When CA125 was combined with HE4,
the prediction rate was higher, showing a sensitivity for detecting
malignant disease of 76.4% at a specificity of 95% (Moore et al,
2008b). Subsequently, Moore et al (2009) performed a multicentre
prospective study including 531 women diagnosed with a pelvic
mass who underwent surgery. Patients were classified as being
at a high or low risk for ovarian cancer with a specificity of 75.0%
and a sensitivity of 92.3% for post-menopausal patients, and
a specificity and sensitivity of 74.8 and 76.5%, respectively, for
pre-menopausal patients.
In this study, we aimed to independently validate HE4 and
the combination of HE4 with CA125 using the Risk of Ovarian
Malignancy Algorithm (ROMA) for the diagnosis of ovarian
cancer.
PATIENTS AND METHODS
Patients
From August 2005 to March 2009, 389 patients were included in
a prospective study conducted at the University Hospitals Leuven.
All patients were diagnosed with a pelvic mass of suspected
ovarian origin and were scheduled for surgical intervention.
Women with a previous bilateral oophorectomy were not eligible.
All patients underwent imaging by pelvic ultrasound to document
the presence of an ovarian mass. Clinical information was
retrieved from the patients’ hospital notes. All patients underwent
surgical removal of the ovarian mass, and if a patient was
diagnosed with an ovarian cancer, then surgical staging was
performed.
Before the collection of biological samples and surgery, all
patients were required to give fully informed consent. The protocol
was approved by the Local Ethics Committee. The Ethical
Committee released the authors from the obligation to obtain an
insurance contract because of the character of this study. Patient
participation in the study was concluded once the final surgical
pathology reports were obtained.
Serum samples
Immediately before surgery, blood samples were obtained.
Blood samples were collected in 10ml clothing activating tubes
(BD Vacutainer Serum Tube, ref. 369033; Becton-Dickinson,
Erembodegem, Belgium). Serum tubes were centrifuged at 800g
for 10min. Serum was collected, dispensed into multiple cryotubes
and frozen at  801C. The time between blood sampling and
freezing of the serum and presence of haemolysis was noted. The
targeted time limit between sampling and freezing was 4h.
Marker assays
Serum CA125 concentrations were measured using the CanAg
CA125 EIA assay (Fujirebio Diagnostics, Go ¨teborg, Sweden)
and serum HE4 concentrations were measured using the HE4
EIA assay (Fujirebio Diagnostics). Both assays are solid-phase,
non-competitive immunoassays, based on the direct sandwich
technique, and were run according to manufacturer’s instructions.
Each ELISA was performed manually and in duplicate for
calibrators, controls and patient samples. The appropriate controls
were within the ranges provided by the manufacturer for all
runs. For CA125, the normal upper limit was 35Uml
 1, whereas
that for HE4 was 70pM (as suggested by Moore et al (2008b) or
150pM (as suggested in the product insert). A cutoff point that
provided the best accuracy (minimal false-negative and false-
positive results) in the study was also determined. We also
determined our own ideal cutoff, corresponding to the highest
accuracy.
Statistical analysis
ROMA classifies patients as being at a low or at a high risk for
malignant disease using the following algorithms:
  Premenopausal: predictive index (PI)¼ 12.0þ(2.38 LN(HE4))þ
(0.0626 LN(CA125))
  Postmenopausal: PI¼ 8.09þ(1.04 LN(HE4))þ[0.732 
LN(CA125))
  Predicted probability: (PP)¼100   exp(PI)/(1þexp(PI))
According to the manufacturer’s insert, the following thresholds
were selected for ROMA:
  Pre-menopausal women:
* PP X12.5%¼high risk of finding EOC
* PP o12.5%¼low risk of finding EOC
  Post-menopausal women:
* PP X14.4%¼high risk of finding EOC
* PP o14.4%¼low risk of finding EOC
Statistical analysis was performed with MedCalc v11.1.1.0
(MedCalc Software, Mariakerke, Belgium) and with PASW
Statistics v17.0 (SPSS, Brussels, Belgium). The mean age of the
patients was compared using Student’s t-test, and categorical
variables were compared with the w
2-test. Tumour marker
levels were compared using the Wilcoxon rank-sum test
(Mann–Whitney two sample statistic) or the Kruskal–Wallis rank
test (multiple sample statistic).
Receiver operator characteristic (ROC) curves were constructed,
and the area under the curve (ROC–AUC) with a 95% confidence
interval was calculated. Sensitivity and specificity were calculated
in pre- and post-menopausal women separately and independently
of menopausal status. Subgroups were analysed according to the
histological subtype of the tumour, stage, grade, use of hormonal
drugs, smoking habit, familial history, presence of haemolysis and
the time between sampling and freezing. The method described by
DeLong et al (1988) was used for the calculation of the difference
between two ROC–AUCs. For all statistical comparisons, a P-value
of o0.05 was considered statistically significant.
RESULTS
Patient characteristics
The serum of 389 patients was analysed: 228 (58.6%) patients had
benign disease and 161 (41.4%) patients had malignant disease
(Table 1). Patients with benign disease were younger and more
likely to be pre-menopausal. Patients with malignant disease were
more likely to have a family history of breast and ovarian cancer.
Table 1 Distribution of patient characteristics for patients with a benign
or malignant pelvic mass
Variable Numerical display Benign Malignant P-value
Number of cases n (%) 228 (58.6) 161 (41.4) NA
Age (in years) Mean (s.d.) 46.3 (16.0) 57.8 (12.6) o0.001
Post-menopausal n (%) 86 (37.7) 119 (73.9) o0.001
Smoking n (%) 53 (23.2) 31 (19.3) 0.457
OC
a n (%) 44 (31.2) 12 (30.0) 0.682
HRT
b n (%) 14 (16.3) 9 (7.6) 0.053
Family history
Breast cancer n (%) 35 (15.4) 41 (25.5) 0.009
Ovarian cancer n (%) 4 (1.8) 8 (5.0) 0.028
Abbreviations: HRT¼hormone replacement therapy; OC¼oral contraception;
NA¼not applicable.
aFor pre-menopausal patients.
bFor post-menopausal patients.
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Overall, 40 samples were not frozen within a time limit of 4h
after sampling, of which 24 (10.5%) were from benign cases and
16 (9.9%) were from malignant cases (P¼0.851). Haemolysis
was noted in 38 cases, of which 23 (10.1%) were from benign cases
and 15 (9.3%) were from malignant cases (P¼0.801).
Tumour characteristics
The most common benign ovarian tumours were cystadenomas
(n¼52), cystadenofibromas (n¼26), endometriomas (n¼66)
and mature teratomas (n¼29) (Tables 2 and 3). Mixed tumours
(n¼16) contain two or more different histological subtypes,
making it impossible to categorise these tumours into a specific
subtype. The cystadenomas and cystadenofibromas included
47 serous, 26 mucinous and 5 other histological types or mixed
cystadenomas/cystadenofibromas. The majority of the malignant
tumours were EOC. Most of the EOC were of high grade and were
diagnosed at an advanced stage. Other primary non-epithelial
ovarian tumours (NEOCs) included two sex cord stromal tumours
and two sarcomas. All other malignant tumours of the ovary
(n¼26) were metastases from extra-ovarian primary tumours.
These tumours were mainly of an endometrial or gastrointestinal
origin.
Tumour marker levels
The median CA125, HE4 and ROMA serum levels differed
significantly between benign and malignant cases for the whole
group, and for the pre- and post-menopausal groups separately
(Po0.0001 for all comparisons) (Table 4, Figures 1 and 2). Within
the benign group, the most frequent tumours were analysed. Using
Kruskal–Wallis rank test, we found the median tumour marker
levels to be statistically different for CA125 (Po0.0001), HE4
(P¼0.0043) and ROMA (P¼0.0006). Post hoc pairwise compar-
isons with the Wilcoxon rank-sum test showed that CA125
was significantly elevated in endometriosis and ovarian fibro-
mas/thecomas compared with cystadenomas/cystadenofibromas
(Po0.0001 and P¼0.0111), functional cysts (P¼0.0160 and
P¼0.0281) and mature teratomas (P¼0.0002 and P¼0.0169).
For HE4, the only significant comparison found was the pairwise
comparison between cystadenomas/cystadenofibromas and endo-
metriosis (P¼0.0002). Risk of Ovarian Malignancy Algorithm
was significantly elevated in cystadenomas/cystadenofibromas
(Po0.0001) and ovarian fibromas/thecomas (P¼0.0111) when
compared with endometriosis, and in cystadenomas/cystadeno-
fibromas when compared with mature teratomas (P¼0.0349).
Within the group of malignant tumours, there was no significant
difference between the CA125, HE4 and ROMA levels of EOC and
metastatic tumours. There was no significant difference between
FIGO stages I and II tumours, nor between FIGO stages III and IV
tumours, although the difference between early (FIGO I–II) and
advanced stages (FIGO III–IV) was significant for CA125, HE4 and
ROMA. There was a significant difference between borderline
and invasive disease (grades 1–3) for all markers, but there was no
difference among grades 1, 2 and 3 for the different markers.
ROC curves and performance indices for all tumours
The ROC–AUC of CA125 was not significantly different from that
of HE4 or ROMA for all malignant diseases (including EOC,
NEOC and metastases) compared with benign disease (Table 5,
Figure 3). Pairwise comparison of ROC–AUCs showed that only
the difference between HE4 and ROMA was significant. For pre-
menopausal patients, again, only the pairwise comparison between
HE4 and ROMA was significant. In the post-menopausal popula-
tion, there was a significantly better performance of CA125 vs HE4,
and of ROMA vs HE4. Overall, ROMA did not perform signi-
ficantly better than CA125 alone, either for the whole group of
patients or for the pre- or post-menopausal patients separately.
At the ideal cutoff, corresponding to the highest accuracy
(minimal false-negative and false-positive results), CA125, HE4
and ROMA resulted in a similar sensitivity and specificity within
the different menopausal groups. Sensitivity and specificity using
Table 2 Histological type and distribution of benign disease
Histological type n %
Cystadenoma/cystadenofibroma
a 78 34.1
Endometriosis 66 28.9
Mature teratoma 29 12.7
Fibroma/thecoma 15 6.6
Functional cyst 13 5.7
Hydrosalpinx 3 1.3
Abces 2 0.9
Parasalpingeal cyst 2 0.9
Struma ovarii 2 0.9
Leydig cell tumour 1 0.4
Unknown 1 0.4
Mixed 16 7.0
Total 228 100.0
aIncluding 47 serous, 26 mucinous and 5 other or mixed cystadenomas/
cystadenofibromas.
Table 3 FIGO stage, differentiation grade and histological type of
malignant disease
n %
Histological type
Epithelial 131 81.4
Serous 84 52.2
Mucinous 21 13.0
Endometrioid 7 4.3
Clear cell 6 3.7
Mixed 6 3.7
Carcinosarcoma 4 2.5
Undifferentiated 3 1.9
Granulosa cell 2 1.2
Sarcoma 2 1.2
Metastatic 26 16.1
Endometrium 11 6.8
Colon 5 3.1
Appendix 3 1.9
Mesothelioma 2 1.2
Breast 1 0.6
Lung 1 0.6
Lymphoma 1 0.6
Pancreas 1 0.6
Stomach 1 0.6
Total 161 100.0
FIGO stage
a
I 43 32.8
II 8 6.1
III 66 50.4
IV 14 10.7
Total 131 100.0
Differentiation grade
a
Borderline 31 23.7
Grade 1 13 9.9
Grade 2 14 10.7
Grade 3 73 55.8
Total 131 100.0
Abbreviation: FIGO¼International Federation of Gynecology and Obsterics.
aFor epithelial ovarian cancer only.
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ROMA are also shown in Table 5, together with the sensitivity and
specificity of HE4 at a cutoff of 70pM.
ROC curves for subgroups
When EOC was analysed alone and NEOC and metastatic tumours
were excluded, the ROC–AUC of ROMA was higher (Figure 4,
Supplementary Table 1). The ROC–AUC was even higher when all
borderline tumours were excluded. With regard to histological
subtypes, a comparison of ROC–AUC of (pure) serous with that
of non-serous EOC (excluding all mixed serous tumours) showed
that ROC–AUC of ROMA was higher for the serous subtype.
In contrast, all markers performed significantly worse when only
the mucinous subtype was examined.
DISCUSSION
This study aimed to investigate the performance of serum
tumour markers CA125 and HE4, and the risk stratification tool
ROMA in a prospective collection of serum samples from patients
with an ovarian mass. We found that there was a significant
difference between benign and malignant disease with respect
to serum CA125, HE4 and ROMA levels. When the ROC–AUCs of
the different tumour markers were compared, HE4 and CA125
performed similarly, except for the post-menopausal patients in
whom CA125 performed better. This similar performance of
HE4 and CA125 was also noted in other studies (Hellstrom et al,
2003; Scholler et al, 2006; Palmer et al, 2008; Montagnana et al,
2009; Andersen et al, 2010). Combining HE4 and CA125 in the
ROMA improved HE4 but not CA125 performance, regardless
of menopausal status. As CA125 is the current standard for
comparison, this means that neither HE4 nor the ROMA improved
the diagnosis of ovarian cancer. This is in contrast to the results
of Moore et al (2008b), who found that a combination of CA125
and HE4 performed better than CA125 alone. However, Moore
et al (2008b) excluded all borderline tumours, NEOC and
metastatic tumours to calculate the performance of the tumour
markers they tested. We decided not to exclude these tumours in
our initial analysis as we wanted to study a patient population that
reflected a normal clinical setting. When borderline tumours,
NEOC and metastatic cancers were excluded, the ROC–AUC for
CA125 was 0.937 vs 0.836 in the study by Moore et al (2008b).
In contrast, the ROC–AUCs of HE4 were similar: 0.914 (our data)
vs 0.908 (Moore et al, 2008b). In a more recent study, Moore et al
(2010) also included borderline tumours in their analysis. Within
this study, the examination of benign cases vs all stages of EOC and
borderline tumours revealed an ROC–AUC of 0.913. Within a
setting of a multicentre prospective trial with central review and
monitoring it seems plausible that a diagnostic test would perform
slightly better.
Compared with CA125, HE4 is inversely influenced by age;
whereas CA125 is higher in healthy pre-menopausal patients (Bon
et al, 1996; Bonfrer et al, 1997), HE4 tends to be higher in post-
menopausal patients (Moore et al, 2008a, 2008b; Andersen et al,
2010). These slightly higher normal values influence the perfor-
mance of the tumour markers concerned. Although not significant,
this can also be seen in our study population: the ROC–AUC of
CA125 was higher in the post-menopausal group. Of particular
interest, HE4 seems to have a slightly higher ROC–AUC in the pre-
menopausal group than in the post-menopausal group. Although
this difference is not significant, it causes the ROC curves of CA125
and HE4 to come together in the pre-menopausal group and
diverge in the post-menopausal group (Figure 3). In other words,
the performance of HE4 is similar to that of CA125 in the pre-
menopausal group, but significantly worse in the post-menopausal
group. This increased performance of HE4 in the pre-menopausal
group is in agreement with previous studies (Moore et al, 2008b;
Andersen et al, 2010), and confirms that CA125 and HE4 function
independently of each other.
Owing to the fact that ROC curves are not used in clinical
practice, we aimed to find the cutoff points for the different
tumour markers. The cutoff values corresponding to the highest
accuracy (minimal false-negative and false-positive results) for
all patients were 62.5kUl
 1 for CA125, 72.2pM for HE4 and 22.2%
for ROMA. In the product insert, it is suggested that 94.4% of
the healthy female subjects (n¼179) that were studied had a
HE4 value of 150pM or below. If we define the reference value as
the value that includes 95% of healthy controls, and we use this
Table 4 Serum CA125, HE4 and ROMA levels according to histology, FIGO stage and tumour grade
CA125 (Uml
 1) HE4 (pM) ROMA (%)
Median IR Median IR Median IR
Benign histology 12.8 8.0–27.6 45.4 35.6–60.8 6.8 3.9–11.9
Cystadenoma/cystadenofibroma 11.3 7.4–19.5 53.7 40.8–68.0 9.1 5.7–14.4
Endometriosis 25.5 10.7–54.9 40.0 34.3–50.7 4.9 3.3–7.5
Fibroma/thecoma 29.1 11.6–45.5 48.1 33.9–73.2 11.6 5.0–24.7
Functional cyst 10.5 6.8–20.7 43.7 30.8–54.6 6.2 3.0–9.4
Mature teratoma 9.8 5.7–15.9 43.9 37.5–52.5 5.6 3.4–10.9
Malignant histology 276.5 52.4–1195.9 151.8 67.4–560.4 76.1 25.7–96.5
Epithelial ovarian cancer 321.3 50.2–1291.4 184.6 72.9–589.3 79.6 28.1–96.7
Metastatic 222.9 64.9–913.5 103.5 48.9–302.4 55.0 9.7–92.5
FIGO stage
I 38.4 16.9–182.6 73.2 52.6–126.5 25.6 11.8–64.3
II 60.2 20.6–254.8 69.0 44.3–152.6 45.5 26.1–56.2
III 757.3 227.9–1640.0 308.0 135.0–712.5 91.2 70.3–98.4
IV 1260.7 790.6–2905.1 578.7 274.6–2612.9 98.0 93.0–99.5
Tumour grade
Borderline 38.3 14.8–170.4 67.6 52.6–116.4 23.4 10.0–50.1
Grade 1 379.4 83.2–1120.4 119.9 72.7–336.5 74.5 52.2–94.9
Grade 2 755.7 124.2–945.4 552.9 125.0–844.3 94.3 67.8–97.6
Grade 3 748.7 112.1–1580.9 274.6 97.8–716.7 90.3 59.2–98.4
Abbreviations: FIGO¼International Federation of Gynecology and Obstetrics; HE4¼human epididymis secretory protein 4; IR¼interquartile range; ROMA¼Risk of Ovarian
Malignancy Algorithm.
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a sensitivity of 50.3% and a specificity of 96.5%. In clinical
practice, this means that 3.5% of patients with a benign tumour
will be treated as if they had a malignant tumour (overtreatment),
and 49.7% of patients with a malignant tumour will be treated
as if they had a benign tumour (undertreatment). Therefore,
in our study, this cutoff point is not useful for differentiating
benign from malignant cysts. Andersen et al (2010) also
determined their cutoff at the 95th percentile in a healthy control
group. On the basis of this cutoff, they obtained a sensitivity of
77.0% and a specificity of 94.9%. Unfortunately, they failed to
mention what their cutoff value was. Using the cutoff point of
70pM, as previously suggested by Moore et al (2008b), we reached
a sensitivity of 74.5% and a specificity of 83.3%. This is there-
fore comparable to our ideal cutoff point of 72.2pM, and is thus
a reasonable cutoff point for HE4. With regard to ROMA, different
cutoff points are used in pre-menopausal and post-menopausal
patients. Both cutoff points are determined to provide a specificity
level of 75% for the CA125 plus HE4 assay combination. Our
ideal cutoff points of 16.6% for the pre-menopausal patients and
35.9% for the post-menopausal patients were somewhat different
from those suggested previously. However, these were not
established at 75% specificity, but at the point on the ROC curve
at which we had minimal false-negative and false-positive results.
Irrespective of whether we analyse only invasive EOC, our ideal
cutoff point in the pre-menopausal and post-menopausal category
is higher than the suggested cutoff points of 12.5 and 14.4%,
respectively.
As expected, histological subtypes seem to be important for the
performance of the different tumour markers. With regard to
benign tumours, it was interesting to see that the fibromas/
thecomas group and the endometriomas had the highest levels of
CA125, whereas for HE4, the endometriomas had the lowest level.
As already mentioned by Huhtinen et al (2009), measuring both
CA125 and HE4 together could be of particular interest in
differentiating endometriosis from ovarian cancer, as ovarian
cancer will cause a raised CA125 and HE4, whereas endometriosis
will only cause a raised CA125. This could explain why HE4
performs better in pre-menopausal patients compared with post-
menopausal patients, and vice versa for CA125. However, even for
the pre-menopausal patients, HE4 and ROMA did not perform
better than CA125. All malignant tumours expressed high levels of
CA125 and HE4, but the highest levels were noted for the serous
subtype. High expression levels of HE4 for the different epithelial
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Figure 1 Box and whisker plots representing median levels and the interquartile range (box) of CA125 (in Uml
 1), HE4 (in pM) and ROMA (in %) for
benign histology subtypes (subset (A), (D) and (G)), benign vs malignant (subset (B), (E) and (H)) and malignant histology subtypes (subset (C), (F)
and (I)). The y axis is a logarithmic scale for CA125 and HE4. Abbreviations: Cystad.¼cystadenoma or cystadeanofibroma; Eosis¼endometriosis;
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ssubtypes, with the exception of the mucinous subtype, were
already noticed in previous studies (Lu et al, 2004; Drapkin et al,
2005; Gilks et al, 2005; Galgano et al, 2006).
Although CA125, HE4 and ROMA are not currently recom-
mended as a screening tool, it is interesting to see how well a
tumour marker performs in the early stage of disease. A definite
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Figure 2 Box and whisker plots representing median levels and the interquartile range (box) of CA125 (in Uml
 1), HE4 (in pM) and ROMA (in %)
at various FIGO stages (subset (A), (C) and (E)) and various grades, including borderline (subset (B), (D) and (F)). The y axis is a logarithmic scale for
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Table 5 Comparison of ROC–AUCs, sensitivity and specificity for CA125 (Uml
 1), HE4 (pM) and ROMA (%) among patients with all types and stages
of ovarian tumours
Pairwise comparison
of ROC–AUC
a
Ideal
cutoff
b
Suggested
cutoff
Menopausal
status Marker
ROC–AUC
(95% CI)
HE4 vs
CA125
HE4 vs
ROMA
CA125 vs
ROMA Cutoff
Sensitivity
(%)
Specificity
(%) Cutoff
Sensitivity
(%)
Specificity
(%)
All patients ROMA 0.898 (0.863–0.926) P¼0.306 Po0.001 P¼0.172 22.2 79.2 88.1 12.5/14.4
c 84.9 79.7
CA125 0.877 (0.840–0.908) 62.5 73.9 89.0 35.0 79.5 81.6
HE4 0.857 0.819–0.891) 72.2 73.9 85.1 70.0
d 74.5 83.3
150.0
e 50.3 96.5
Pre-menopausal ROMA 0.846 (0.785–0.895) P¼0.570 P¼0.044 P¼0.782 16.6 67.5 91.5 12.5
c 67.5 87.9
CA125 0.856 (0.796–0.904) 83.8 70.0 90.1 35.0 75.0 80.1
HE4 0.833 (0.771–0.885) 66.0 67.5 90.8 70.0
d 67.5 90.8
150.0
e 42.5 99.3
Post-menopausal ROMA 0.891 (0.840–0.930) P¼0.001 Po0.001 P¼0.487 35.9 79.0 89.5 14.4
c 90.8 66.3
CA125 0.897 (0.847–0.935) 51.2 76.5 90.7 35.0 81.5 83.7
HE4 0.812 (0.752–0.863) 74.2 74.8 77.9 70.0
d 77.3 70.9
150.0
e 52.9 91.9
Abbreviations: CI¼confidence interval; HE4¼human epididymis secretory protein 4; ROC–AUC¼receiver operator characteristic–area under the curve; ROMA¼Risk of
Ovarian Malignancy Algorithm.
aDifferences in ROC–AUCs were calculated by using the method as described by DeLong et al, 1988.
bCutoff value corresponding to the highest
accuracy (minimal false-negative and false-positive results).
cCutoff values for ROMA: 12.5% for the pre-menopausal patients and 14.4% for the post-menopausal patients, as
suggested in the product insert.
dCutoff value for HE4 at 70pM as suggested by Moore et al, (2008b).
eCutoff value for HE4 at 150pM as suggested in the product insert (17).
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strend could be seen from stage I to stage IV disease, and CA125 and
HE4 performed significantly worse when early and late stages of
disease were compared. As a consequence, the ROMA also
performed worse. With these ROC–AUCs, the chances that HE4
or ROMA will be successful as a screening marker are low, as very
high specificities are required in screening for low prevalent disease.
In summary, this large independent validation study was able
to demonstrate similar performance indices as those recently
published in the literature. However, in our study, neither HE4
nor ROMA increased the detection of malignant disease. Human
Epididymis secretory protein 4, or its combination with CA125,
could be useful in diagnosing certain benign or malignant
subtypes; however, this needs to be explored in more detail.
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Figure 3 ROC curves for CA125, HE4 and ROMA among patients with all types and stages of ovarian tumours. (A) Malignant vs benign disease
in pre- and post-menopausal patients together. (B) Malignant vs benign disease in pre-menopausal patients. (C) Malignant vs benign disease
in post-menopausal patients. Total AUC values for each assay are listed in parentheses.
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Figure 4 ROC curves for ROMA. The ROC curves in the different subsets represent different groups of ovarian cancer (cases) compared with
benign ovarian tumours (non-cases). (A) All malignant tumours, epithelial ovarian cancer (EOC) and invasive EOC (excluding borderline tumours) vs benign
disease. (B) FIGO stages I, II, III and IV vs benign disease. (C) Early stage (stages I and II combined) and advanced stage (stages III and IV combined) vs
benign disease. (D) Grades 1–3 EOC and borderline EOC vs benign disease. (E) Serous EOC and non-serous EOC vs benign disease (all mixed serous
tumours were excluded from this analysis). (F) Mucinous EOC and non-mucinous EOC vs benign disease (all mixed mucinous tumours were excluded from
this analysis). Total AUC values for each assay are listed in parentheses.
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